Scope and Claim Coverage of US Patent 8,101,659 (Valsartan + NEP Inhibitor 1:1 Combination) and the U.S. Patent Landscape
US Patent 8,101,659 is a U.S. composition-of-matter claim set anchored on a fixed 1:1 co-administration ratio of (1) the AT1 antagonist valsartan and (2) a specific NEP inhibitor scaffold (two enumerated alternative NEP inhibitor identities), together in a pharmaceutically acceptable carrier. The patent’s enforceable scope is narrow in structure (only those two drug classes and the specified NEP inhibitor identities) but broad in use/format as to therapy targets (hypertension and heart failure are claimed) and dosage forms (tablet or capsule are claimed in a dependent claim). The most consequential competitive design-around is changing the dosing ratio away from about 1:1 and/or replacing the NEP inhibitor with a non-enumerated NEP inhibitor.
US Patent 8,101,659: What does the patent claim and how broad is it?
Short answer: The core independent claim covers a pharmaceutical composition containing valsartan plus one of two specifically named NEP inhibitors, with the valsartan:NEP inhibitor administered at about a 1:1 ratio in the combination, in a pharmaceutically acceptable carrier.
What is the independent claim scope (Claim 1)?
Claim 1 is a three-part composition definition plus a key dosing constraint:
-
AT1 antagonist component (i):
- Valsartan or a pharmaceutically acceptable salt of valsartan.
-
NEP inhibitor component (ii):
- One of two expressly identified NEP inhibitor structures, either in free base form or salt form:
- NEP inhibitor A: N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester
- NEP inhibitor B: (2R,4S)-5-biphenyl-4-yl-4(3-carboxy-propionyl amino)-2-methyl-pentanoic acid
-
Formulation carrier (iii):
- A pharmaceutically acceptable carrier.
-
Combination dosing ratio requirement:
- Valsartan and the NEP inhibitor are administered in combination in about a 1:1 ratio.
Key scope implications:
- Drug identity constraint: Only valsartan (and its salts) is covered for the AT1 antagonist side; other AT1 antagonists (losartan, irbesartan, candesartan, etc.) are not within Claim 1 as written.
- NEP inhibitor identity constraint: Only the two enumerated NEP inhibitors are covered. NEP inhibitors used in practice that are not those exact chemical entities fall outside Claim 1.
- Carrier flexibility: The claim is compatible with many conventional carrier systems because it only requires a “pharmaceutically acceptable carrier.”
- Dosing ratio constraint is central: “About a 1:1 ratio” is likely the strongest literal-text limitation and the primary design-around lever.
What do the dependent claims add (Claims 2–4)?
Claim 2: therapeutic use limit
Claim 2 narrows Claim 1 to treatment where amounts are effective to treat:
- Hypertension or
- Heart failure.
This does not change the drug combination identities. It changes the claimed use framing and likely supports infringement theories tied to those indications.
Claim 3: narrows NEP inhibitor to NEP inhibitor A
Claim 3 specifies that the NEP inhibitor in Claim 2 (and Claim 1) is:
- N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester (NEP inhibitor A).
This is a further narrowing relative to Claim 1 by excluding NEP inhibitor B.
Claim 4: dosage form restriction
Claim 4 narrows to a specific dosage format:
What does “composition comprising” mean for scope?
“Comprising” supports inclusion of additional excipients and potentially additional active ingredients, but the claim still requires that the composition includes:
- valsartan (or salts),
- the specific NEP inhibitor (or salts), and
- a pharmaceutically acceptable carrier,
with the combination administration ratio as stated.
In practical infringement terms, a product with other actives could still fall within scope if the claim elements are met and the 1:1 ratio requirement is satisfied.
What patents protect valsartan plus NEP inhibitors in the U.S., and how does 8,101,659 fit?
Short answer: US 8,101,659 protects a specific fixed-ratio valsartan + a specific NEP inhibitor pairing. The broader landscape usually includes (a) valsartan composition/formulation patents, (b) NEP inhibitor compound patents, and (c) combination therapy patents that may cover different NEP inhibitors, different ratios, different administration schemes, or different indications and dosage forms. The patent you named is most directly aligned with combination fixed-ratio compositions combining valsartan with a specified NEP inhibitor.
Patent estate structure typically surrounding this pairing
Even without asserting a complete bibliographic claim set here, the estate logic for this therapeutic class generally breaks into three layers:
-
Valsartan chemical/compound and salt/formulation patents
- Coverage often includes salt forms, particle size, crystalline forms, and formulations that improve bioavailability or stability.
-
NEP inhibitor chemical/compound and salt patents
- Coverage often includes the exact NEP inhibitor structures, enantiomers, stereochemistry, and certain salt forms.
-
Combination patents
- Coverage often includes:
- fixed-dose combinations,
- combination dosing schedules,
- ratio windows,
- indication-specific claims (hypertension, heart failure, post-MI, etc.),
- dosage form claims.
Within that structure, US 8,101,659 sits squarely in the combination layer, with the ratio requirement providing the most enforceable differentiator.
Where this claim likely overlaps with other combination claims
The most common overlap patterns for fixed-dose combination patents include:
- the same or similar combination but different ratio (not about 1:1),
- the same combination but different dosage forms (oral suspension, film-coated tablets, etc.),
- the same therapy area but different indication scope (e.g., heart failure with reduced ejection fraction vs broader heart failure).
US 8,101,659’s dependent claims provide additional anchoring points for enforcement:
- hypertension/heart failure (Claim 2),
- NEP inhibitor A specifically (Claim 3),
- capsule/tablet formats (Claim 4).
Which parts of the claim can be targeted for design-around in generics or new fixed-dose products?
Short answer: Change the NEP inhibitor identity, change the valsartan identity, and most directly, avoid “about a 1:1 ratio” co-administration if the product cannot meet the fixed ratio requirement. Dosage form can also be shaped, though independent Claim 1 does not require a capsule or tablet.
Design-around levers
1) NEP inhibitor substitution
- Claim 1 requires either NEP inhibitor A or NEP inhibitor B by explicit name/structure.
- A competing product using a different NEP inhibitor chemical entity does not satisfy the “(ii)” limitation.
2) AT1 antagonist substitution
- Claim 1 requires valsartan (or salt). Other AT1 antagonists do not satisfy “(i).”
3) Ratio shifting away from “about 1:1”
This is the most litigation-relevant lever because it is shared across all dependent claims through incorporation of Claim 1.
Practical ways competitors attempt to shift:
- asymmetrical dose amounts (e.g., 2:1, 1:2),
- different unit strength combinations,
- separate administration timing that avoids a “combined administration in about a 1:1 ratio” characterization (depending on how “administered in combination” is construed).
The claim language ties to the administration in combination and uses “about,” which creates a tolerance argument for defendants. Claim interpretation will determine how tight “about” is, but the core point is: a product engineered away from 1:1 will have a materially stronger non-infringement position than a product that merely tweaks excipients.
4) Dosage form selection
- Only Claim 4 is limited to capsule or tablet.
- If an alternative oral form is used (e.g., oral solution), it may avoid Claim 4 while still potentially infringing Claim 1/2/3 unless those are also avoided via other limitations.
How do the claims map to likely infringement theories (product vs method) and what is “combination administration” in practice?
Short answer: The patent is written as a composition claim but includes a combination administration ratio. Infringement is most straightforward where a fixed-dose combo product is marketed or used with amounts that meet the claimed 1:1 ratio.
Product-use and label-driven theories
In fixed-dose oral therapies, infringement arguments often center on:
- the labeled dosing regimen,
- unit strength and tablet/capsule composition,
- prescribing instructions that set the dose ratio.
For separately dosed components (two-product co-therapy), plaintiffs typically argue:
- the regimen is “administered in combination,” and
- the co-administration amounts are effectively “about 1:1.”
Claim construction pressure points
The definitional pressure points are:
- “about a 1:1 ratio” (numeric tolerance),
- “administered in combination” (concurrent vs sequential administration and practical regimen design),
- what counts as “pharmaceutically acceptable salt” for each component (salts must be within the claim definition).
What is the U.S. exclusivity and expiration timing for US 8,101,659?
Short answer: This depends on the patent’s priority/filing data and any terminal disclaimers and maintenance status. The information provided here does not include the patent’s filing date, priority date, expiration date, or maintenance/term adjustment data. Without those facts, the exclusivity and expiration timeline cannot be stated accurately.
What does the Orange Book status for valsartan + this NEP inhibitor look like?
Short answer: The Orange Book listing status cannot be determined from the claim text alone. Orange Book “patent number” and “listed drug” mapping depends on FDA publication data and the NDA/ANDA product association.
How strong is the patent estate for this specific fixed-ratio combination?
Short answer: Claim strength is high for literal identity matches (valsartan + enumerated NEP inhibitor + about 1:1 ratio) but is constrained by narrow chemical identity coverage.
Strengths
- Clear, objective limitations: valsartan identity and two NEP inhibitor identities.
- Ratio requirement provides a distinct boundary versus broader “combo therapy” claims.
- Dependent claims reinforce:
- indication framing (hypertension/heart failure),
- NEP inhibitor A specificity,
- tablet/capsule formats.
Potential weaknesses (from a competitive freedom-to-operate lens)
- Competitors have multiple explicit off-ramps:
- switch AT1 antagonist,
- switch NEP inhibitor,
- avoid 1:1 ratio.
- If a generic product is engineered to avoid the ratio, it may avoid Claim 1 entirely.
How do you evaluate generic entry risk for products that combine valsartan with NEP inhibitors?
Short answer: Risk is driven less by the general idea “valsartan + NEP inhibitor” and more by whether the product contains the exact NEP inhibitor entity and whether the dosing regimen is “about 1:1.”
Risk matrix (claim element coverage)
| Competitive product design |
Claim 1 element met? |
Generic entry risk vs US 8,101,659 |
| Valsartan + NEP inhibitor A or B + carrier, and dose is about 1:1 |
Yes |
High |
| Valsartan + different NEP inhibitor |
No |
Lower to minimal for Claim 1 |
| Different AT1 antagonist + NEP inhibitor A or B |
No |
Lower to minimal for Claim 1 |
| Valsartan + NEP inhibitor A or B but dosing ratio not about 1:1 |
No (likely) |
Lower to minimal if non-1:1 is maintained |
| Tablet/capsule format only |
Not relevant to Claim 1; may impact Claim 4 only |
Medium overall unless other elements match |
Key takeaways
- What US 8,101,659 covers: A pharmaceutical composition requiring valsartan + one of two specifically defined NEP inhibitors in a pharmaceutically acceptable carrier, with the valsartan and NEP inhibitor administered in about a 1:1 ratio.
- What dependent claims do: They narrow to hypertension/heart failure (Claim 2), NEP inhibitor A specifically (Claim 3), and tablet/capsule (Claim 4).
- Most effective design-arounds: Use a different NEP inhibitor identity, a different AT1 antagonist, or avoid about 1:1 co-administration.
- Why ratio matters: The “about a 1:1” element is likely the central infringement battleground for combination regimens.
FAQs
- Can a fixed-dose combo avoid US 8,101,659 by using valsartan with a different NEP inhibitor but the same dosage ratio?
- What happens if a product uses NEP inhibitor A but changes the dosing ratio from 1:1 to 2:1?
- Does using a tablet or capsule matter for infringement if Claim 4 is not met?
- If valsartan and the NEP inhibitor are dosed separately rather than in a single unit, does “administered in combination” still apply?
- How do “pharmaceutically acceptable salts” expand or constrain design-arounds for valsartan and the NEP inhibitor?
References
- United States Patent 8,101,659 (claims provided in prompt).
